A clinical trial on the booster dose of the vaccine developed by Pfizer and BioNTech submitted to the US Food and Drug Administration (FDA) has concluded that the third injection generates "significantly higher neutralizing antibodies".
"The data we've seen to date suggests that a third dose of our vaccine raises levels of antibodies that significantly exceed those observed after the primary two-dose schedule, "said the CEO of Pfizer, Albert Bourla, it's a statement.
The test concludes that this booster injection provides greater protection against original strain of the coronavirus, as well as against the variants Beta and Delta.
This study has been presented to the FDA, as well as other regulatory entities around the world, to be approved in order to be inoculated in the general population over 16 years of age and not only in immunosuppressed people.
This news comes precisely after it was learned that the US gave the go-ahead on Friday the booster dose to people with a less prepared immune system, such as patients with cancer, HIV or those who have received an organ transplant.
. (tagsToTranslate) booster dose (t) Pfizer (t) generates (t) antibodies (t) "significantly (t) higher (t)" (t) Category: All (t) Category: Company News (t ) Category: US Report (t) Category: International News (t) Category: Others (t) Category: Pulsos (t) Category: Pulsos USA (t) mostread_ultimas (t) mostread_fundsnews (t) mostread_empresas (t) mostread_internacional